Company Profile

Encore Vision Inc
Profile last edited on: 4/4/19      CAGE: 508G7      UEI:

Business Identifier: Topical ophthalmic pharmaceutical treatment for presbyopia
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1120 South Freeway Suite 118
Fort Worth, TX 76104
   (540) 278-2545
Location: Single
Congr. District: 33
County: Tarrant

Public Profile

In late December 2016, Encore Vision was acquired by Novartis with the price paid representing a major ROI for Encore Vision investors - all of whom are Angels. Encore Vision is developing a topical ophthalmic pharmaceutical treatment for presbyopia - far sightedness - directed at the cause. The pharmaceutical treatment breaks down excessive biochemical bonds within the crystalline lens that form with age and restores lens softness, thereby allowing the lens to change shape and regain focusing/accommodative ability when focusing on near objects. In-vivo proof of concept in animals has been achieved. Encore Vision had been targeting the growing estimated approximately 1.8 billion presbyope market worldwide of which approximately 100 million are in the United States. Multiple U.S. patents have been issued and multiple U.S. and foreign patent applications are pending

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $150,000
Project Title: Development Of An Eye Drop To Treat Presbyopia

Key People / Management

  William Burns -- President and CEO

  Margaret H Garner

  William Garner -- Chief Scientific Director